Article
The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma
12 Aug 2016
Abstract excerpt
Dear Editor, the incidence of cutaneous squamous cell carcinoma (cSCC) is rising,1 and as there is a lack of effective therapies for inoperable cSCC, new therapeutic options are needed. Immuno‐oncological agents targeting checkpoints such as programmed death‐1 (PD‐1) or its ligand, PD‐L1, are very promising new anticancer drugs, while efficacy correlates with PD‐L1 expression in various tumour types. In order to...